Bomb Report – Lifestyle
Author:
Mabwell (Shanghai) Bioscience Co., Ltd.
Mabwell Establishes a Licensing and Commercialization Agreement for Denosumab Biosimilars in Malaysian Market
April 16, 2026
Global First | NMPA Accepts IND Application for Mabwell’s Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311
April 15, 2026
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)
April 15, 2026
SST001, an α-syn PET tracer from Mabwell’s incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial
April 14, 2026